Health28 May 2026 at 08:17 amQuick read
Junshi Biosciences Phase 3 Study Meets Primary Endpoints
Credibility score90 / 100
LowModerateHigh
2sources verified
Junshi Biosciences announced its phase 3 study met primary endpoints. The study involved stage Ⅱ-Ⅲ NSCLC patients. The final analysis was completed.